Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $476 from $473 and keeps an Equal Weight rating on the shares after Q3 results came in ahead of consensus and the company raised 2024 revenue guidance by about 1% at the midpoint. The next catalyst for the stock will be the suzetrigine Phase 2 lumbosacral radiculopathy, or LSR data, that are still expected by year-end, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Reports Strong Q3 2024 Growth
- VRTX Earnings: Vertex Pharmaceutical’s Financial Results Beat Wall Street Targets
- Closing Bell Movers: Palantir jumps 13% after results
- Vertex raises FY24 product revenue view to $10.8B-$10.9B, consensus $10.75B
- Vertex Pharmaceuticals reports Q3 adjusted EPS $4.38, consensus $4.14